XM
RARE icon

XTX Markets’s Ultragenyx Pharmaceutical RARE Stock Holding History

XTX Markets’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		$246K Sell
1,774
-1,699
-49% -$202K 0.51% 85
2020
Q3 		$285K Buy
+3,473
New +$288K 1.37% 21

Other funds holding RARE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

XTX Markets's RARE Position: Q4 2020 in Review

XTX Markets reduced its Ultragenyx Pharmaceutical (RARE) stake by 49% in Q4 2020, selling an estimated $202K and leaving 1,774 shares worth $246K. The position accounts for 0.51% of the portfolio, ranked #85.

XTX Markets first reported a position in RARE in Q3 2020 and has held it in 2 quarters since. The position peaked at $285K in Q3 2020. 253 funds tracked by Wall St. Rank hold RARE as of Q4 2020.

  • XTX Markets held 1,774 shares of Ultragenyx Pharmaceutical worth $246K as of Q4 2020.
  • XTX Markets sold 1,699 Ultragenyx Pharmaceutical shares in Q4 2020, an estimated $202K.
  • Ultragenyx Pharmaceutical made up 0.51% of XTX Markets's portfolio in Q4 2020, its #85 holding.
  • XTX Markets first reported a position in Ultragenyx Pharmaceutical in Q3 2020 and has held it in 2 quarters since.
  • XTX Markets's Ultragenyx Pharmaceutical position peaked at $285K in Q3 2020.
  • 253 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q4 2020.

Based on XTX Markets's 13F filing for Q4 2020, filed 25 Jan 2021.